TARRYTOWN, N.Y.--(BUSINESS WIRE)--PGI Drug Discovery LLC (PsychoGenics), announced that the Company has extended its drug discovery and development collaboration with Sunovion Pharmaceuticals Inc. (Sunovion) for another four years.
In August 2007, PsychoGenics and Sunovion entered into a drug discovery and development agreement to combine their complementary strengths and expertise to screen compound libraries and identify a new generation of treatments for neuropsychiatric disorders. Since then the companies have expanded the scope of the collaboration, which has led to the identification of potential drug candidates including a compound in clinical development.
Help employers find you! Check out all the jobs and post your resume.
In August 2007, PsychoGenics and Sunovion entered into a drug discovery and development agreement to combine their complementary strengths and expertise to screen compound libraries and identify a new generation of treatments for neuropsychiatric disorders. Since then the companies have expanded the scope of the collaboration, which has led to the identification of potential drug candidates including a compound in clinical development.
Help employers find you! Check out all the jobs and post your resume.